Compare ELWS & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELWS | MRKR |
|---|---|---|
| Founded | 2018 | N/A |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.8M | 16.6M |
| IPO Year | 2023 | N/A |
| Metric | ELWS | MRKR |
|---|---|---|
| Price | $7.10 | $2.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.17 |
| AVG Volume (30 Days) | 26.6K | ★ 547.5K |
| Earning Date | 03-02-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,083,071.00 | ★ $4,694,988.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 145.52 | N/A |
| 52 Week Low | $1.64 | $0.81 |
| 52 Week High | $10.50 | $4.07 |
| Indicator | ELWS | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 64.84 | 63.59 |
| Support Level | $5.40 | $1.93 |
| Resistance Level | $6.34 | $2.29 |
| Average True Range (ATR) | 0.81 | 0.26 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 90.00 | 60.92 |
Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.